Oral Solid Dosage Pharmaceutical Formulation Market Key Players – AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc.

Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential. Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.

Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential. Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.

Future Market Insights (FMI), in its report, projects the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027. In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.

North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation

North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe. Revenue from the market in North America is expected to surpass US$ 300,000 Mn by 2027-end. In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027. Latin America is expected to be the fastest growth region in the market, expanding at 9.2% CAGR through 2027. In contrast, Japan will witness a sluggish growth in the market.

By dosage form, tablets will continue to remain preferred in the market, with sales estimated to surpass US$ 500,000 Mn by 2027-end. Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules. Capsules are expected to be the second most lucrative dosage form in the market, expanding at 6.1% CAGR through 2027.

To remain ‘ahead’ of your competitors, request for a sample

Immediate Release to Remain Dominant in the Market during 2017-2027

Based on release mechanism, immediate release will remain dominant in the market, expanding at 6.4% CAGR through 2027. Immediate release is expected to generate revenue over US$ 400,000 Mn by 2027-end. Controlled release under extended release segment, is expected to register 7.4% CAGR through 2027.

Retail pharmacy is expected to be the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end. Retail pharmacy is expected to exhibit highest CAGR in the market through 2027. In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.

Increasing Presence of MNCs to Drive Market Growth in Latin America

Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources. Multinational companies are focusing on expanding their presence in this region. These factors are expected to propel market growth in Latin America. Oral solid dosage forms are cost-effective and comparatively easy to manufacture than other dosage forms. They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.

Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region. Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity. This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ. However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2782

Key Players identified in FMI’s report include:

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • Hoffman-La-Roche Ltd.
  • Johnson & Johnson
  • Biogen Inc.
  • Bayer AG
  • Teva Pharmaceticals
  • Amgen Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Shire Plc.
  • Celgene Corporation
  • Astellas Pharma Inc.

Market segmentation

By Dosage Form

  • Tablets
  • Capsules
  • Powders
  • Others

By Drug Release Mechanism

  • Immediate Release
  • Extended Release
    • Sustained Release
    • Controlled Release
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores
  • Online Pharmacy

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2782

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa

Endometriosis Treatment Market is expected to exhibit a CAGR of around 3% over the forecast 2021-2030

Rising prevalence of endometriosis condition has fueled the demand for endometriosis treatment across the world. High focus on the introduction of therapeutically-advanced endometriosis treatment options are expected to propel the growth of the market over the forecast period. Leading industry players are significantly accelerating the development of scientific and clinical therapeutic agents and new product launches in the global endometriosis treatment market. This considerable push by industry players is expected to drive future market growth.

Increasing investments in the endometriosis treatment market by key stakeholders and rising awareness among women are the major factors expected to drive market growth. The global endometriosis treatment market was valued at US$ 2.8 Bn in 2018, and is expected to exhibit a CAGR of around 3% over the forecast period (2019-2030).

“Continuous technological advancements towards the development of non-invasive diagnosis techniques for endometriosis and increasing prevalence of gynecological diseases around the globe are projected to accelerate the growth of the global endometriosis treatment market over the coming years.”

Prominent Players:

  • AbbVie Inc.
  • Bayer AG
  • AstraZeneca
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Ipsen Pharma
  • Myovant Sciences Ltd
  • Endoceutics, Inc.
  • Debiopharm Group
  • Mayne Pharma Group Limited

To remain ‘ahead’ of your competitors, request for a sample

Key Takeaways of Endometriosis Treatment Market Study

  • Based on drug, oral contraceptives contributed maximum value share to the global endometriosis treatment market in 2018, owing to high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
  • High treatment efficacy and acceptance with low risk are expected to result in notable share of hormonal therapy in the treatment type.
  • The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of value share to the endometriosis treatment market, owing to the high patient pool in hospitals and visiting retail pharmacies.
  • Europe captured a notable revenue share of 37% in 2018, and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
  • Increasing government expenditure for high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment market across this region.

Multiple New Indications – Imperative Strategy for Market Players

Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa™ (elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3870

What else is in the report?

Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on drug (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • LNR-IUDs
  • Others

Treatment Type

  • Hormonal Therapy
  • Pain Management

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • e-Commerce

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3870

Appendage Management Market Expected to Expand at a CAGR of 6.7% 0ver the Forecast Period 2021-2028

Providing a detailed assessment of the potential opportunities in atrial fibrillation treatment, Future Market Insights’ recent analysis of the global demand for appendage management showcases a promising future for mechanical appendage closure devices. FMI offers a 10-year assessment, 2018-2028, of the global appendage management market, combined with an analysis of the key market influencers.

“Atrial fibrillation, being one of the most complex condition—increases as the life expectancy increases. Moreover, high mortality and morbidity rates associated with atrial fibrillation, considering the occurrence of embolic events including stroke, is a key major contributing significantly to the appendage management landscape—projected to represent a robust Y-o-Y growth rate of 6.3 percent through 2019, reaching a valuation of approximately US$ 196.2 Million for the same period” predicts a senior healthcare analyst

To remain ‘ahead’ of your competitors, request for a sample

Key Insights on Competitive Landscape Analysis of Global Appendage Management Market

As per the FMI analysis, given the high revenue contribution by top five players—including Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Cardia, Inc., and Medtronic plc—holding an accumulative revenue share of nearly 89 percent, the global appendage management market showcases a highly consolidated landscape. FMI’s research also indicates that smaller players, contribute approximately 11.5 percent revenue share to the global appendage management market. A much more careful competitive landscape analysis of the global appendage management market reveals a 3-tier segmentation—depending upon the growth stage of various companies.

  • With reach wide enough in North America, Boston Scientific Corporation and AtriCure, Inc. are the clear market leaders—for endocardial and epicardial left atrial closure devices, respectively. With an accumulative share of approximately 57 percent in the appendage management market, Boston Scientific Corporation’s WATCHMAN and AtriCure, Inc.’s products are in direct competition. However, WATCHMAN is most widely implanted and trusted—boasting FDA approval and CE Mark
  • Mid-stage growth companies including Abbott Laboratories and Cardia, Inc have pulled away from the top two players, in the last few years—holding approximately 32 percent market share. These companies, however, have an expansive range of product offerings. Holding nearly 14 percent in terms of revenue, Abbott Laboratories is upping its portfolio of upper and lower extremities along with popularization of the product with good clinical trial results.
  • The emerging players, including SentreHEART, Inc., LifeTech Scientific Co., Ltd, Occlutech International AB, and Johnson & Johnson Services, Inc. are more focused on product innovation and differentiation within certain treatment niches, to build a strong market position in the consolidated appendage management landscape. In spite of a miniscule market share, FMI foresees notable potential of their research and development initiatives in the long run.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-7752

In terms of overall forward market strategies, key companies are projected to focus on innovating easily implantable, life-saving products for patients suffering from atrial fibrillation, thereby, eliminating the side-effects caused by drugs taken to treat atrial fibrillation. Innovative devices and better navigation and visualization technologies are expected to bring significant opportunities—translating into increased adoption of Left Atrial Appendage (LAA) closure devices by catheterization laboratories and hospitals.

Moreover, mergers and acquisitions will remain a key expansion strategy among players in appendage management market. FMI indicates that acquisitions in the global appendage management market would prove beneficial for the key leaders considering the increasing number of promising on-going or successful researches by emerging companies. Already in a dominant position, key players are increasingly focusing in strengthening the supply chain and distribution networks through strategic partnerships to maximize their market share.

Competitive Landscape

This section of the report features profiles of key players operating in the appendage management market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Some of the key players featured in this report include

  • Abbott Laboratories
  • AtriCure, Inc.
  • Boston Scientific Corporation
  • Cardia, Inc.
  • Johnson & Johnson Services, Inc.
  • LifeTech Scientific Co., Ltd
  • Medtronic plc.
  • SentreHEART, Inc.
  • Occlutech International AB.

Boston Scientific Corporation offers the most trusted product for appendage management, named WATCHMAN device. WATCHMAN device is an endocardial left atrial appendage closure device for occlusion of left atrial appendage. Boston Scientific is launching next-generation WATCHMAN devices with improved and additional features to continue domination in appendage management market.

The key manufacturers of appendage management are focusing on acquisitions and mergers to extend their product portfolio. Launching of new and innovative products is also a strategy followed by the players that is working in their favor.

The companies are conducting conferences and training sessions in hospitals and institutes to enlighten surgeons and practitioners with the improved technology and novel product left atrial appendage closure devices in the appendage management market.

Bonus: Key Market Influencers

  • Notable success rate of appendage management procedures.
  • Non-surgical, minimal invasion approach helping in fast recovery and reduced surgical and implantation complications.
  • Drawback of oral anticoagulant drugs to push the demand for appendage management procedures.

Additional Questions Answered

Some of the additional questions addressed in this report on appendage management market-

  • What is the revenue potential of epicardial and endocardial left atrial appendage closure device in appendage management market across regions of North America and Europe?
  • Who are the key competitors and what are their portfolios in appendage management market?
  • What are major challenges influencing the growth of appendage management market?
  • How intervention from regulatory authority is shaping the appendage management market growth?

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-7752

Segmentation

The report offers a comprehensive taxonomy of the appendage management market based on product type, end user and region. The appendage management market is categorized into two types of products that are epicardial LAA closure devices and endocardial LAA closure devices. These mechanical closure devices in appendage management are used by catheterization and hospitals for appendage management.

Thus, the end-use segments in appendage management market which are a part of this appendage management market report include catheterization laboratories and hospitals. The appendage management market has been analyzed across regions of North America, Latin America, Europe, Asia Pacific (APAC), and MEA.

Surgical Scalpels Market valuation in excess of US$ 1400 Million by the end of Forecast, with CAGR of 3.8% during 2021-2027

Surgical scalpels are available in different types all over the world. Disposable surgical scalpels comprise a frangible handle, a cutting blade and a sheath in a single unit assembly. The other types include reusable surgical scalpels, stainless steel surgical scalpels, high grade carbon steel surgical scalpels, etc.

A new report by Future Market Insights titled ‘Surgical Scalpels Market: Global Industry Analysis 2012 –2016 and Opportunity Assessment 2017 – 2027’ gives a complete overview of the global surgical scalpels market. It includes a comprehensive market analysis that provides information of the market size, Y-o-Y market growth, and segmental comparison, trends governing the market, opportunities available to companies, revenue growth drivers and also the restraints limiting the market’s overall growth. According to the research forecast, the global surgical scalpels market is expected to hold a market value of over US$ 1,000 Mn in 2017 and reach a market valuation in excess of US$ 1400 Mn by the end of 2027, with CAGR of 3.8% during 2017-2027.

Global Surgical Scalpels Market: Dynamics

There are a lot of factors impacting the global surgical scalpels market both negatively and positively. The major drivers of the market’s growth are a rise in the volume of surgical procedures, increase in the number of health care facilities worldwide and less regulatory requirements for product launch. All these factors have contributed to the growth of the global surgical scalpels market revenue. Surgeons are more inclined towards the use of traditional scalpels because of their comfort level and also because traditional scalpels are available easily and at a low price.

However there are also a few factors that have a negative impact on the market, such as an increase in the risk of injury due to the use of scalpels, increased concerns over the safe disposal of used scalpels and increase in alternatives to traditional surgeries.

To remain ‘ahead’ of your competitors, request for a sample

Global Surgical Scalpels Market: Key Segmental Highlights

The market is segmented into various categories to simplify the study and understanding of the global surgical scalpels market. Here are some of the key highlights of the global surgical scalpels market segments:

  • Among the product type segments, the disposable surgical scalpel segment dominated the global surgical scalpels market in 2016 and is projected to be the most dominant and lucrative market throughout the forecast period. The reusable surgical scalpels segment is expected to grow at a CAGR of 3.5% during the forecast period.
  • In the material type segmentation, stainless steel surgical scalpels are expected to lead the market during the forecast period, with a market size of a little under US$ 434 Mn in 2017, leaving behind the high grade carbon steel market that is estimated to reach a value of about US$ 248 Mn in 2017.
  • In the end user segmentation, the hospitals segment dominated the global surgical scalpels market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. It is followed by the ambulatory surgical centres segment with a market value of over US$ 170 Mn in 2017.
  • Among the various regional markets, APEJ is forecasted to be the dominating market during 2017-2027. The APEJ surgical scalpels market is expected to grow at the highest CAGR of 4.1% and reach a market value of just over US$ 415 Mn by the end of 2027. North America is expected to be the second largest market for surgical scalpels in terms of value and is anticipated to grow at the second highest CAGR of 4.0%.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3398

Global Surgical Scalpels Market: Competitive Landscape

This comprehensive research report consists of a brief on the competitive scenario of the global surgical scalpels market. It gives complete profiles of the key market players including their current market plans and future growth strategies. Some of the companies featured in the report are

  • Swann-Morton Limited
  • Hill-Rom
  • PL Medical Co.
  • LLC.
  • VOGT Medical
  • Medtronic Plc.
  • Hu-Friedy Mfg. Co.
  • LLC etc.

Methodical Segmentation of the Global Surgical Scalpels Market

Product Type

  • Disposable Surgical Scalpels
  • Reusable Surgical Scalpels
    • Scalpel Handles
    • Surgical Blades

Material Type

  • Stainless Steel
  • High Grade Carbon Steel
  • Others

End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Nursing Centres
  • Reference Laboratories

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3398

Region

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • APEJ
  • Japan
  • Middle East & Africa

Prothrombin Complex Concentrates Market is projected to expand at a CAGR of 3.5% over the forecast period 2021-2028

A new study by the company titled ‘Prothrombin Complex Concentrates Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028’, has listed out the key points being considered by the companies operating in the prothrombin complex concentrates market to emerge and stay sustainably profitable in the long run. The North America prothrombin complex concentrates market is projected to expand at a CAGR of 3.5% over the forecast period. North America and Western Europe are expected to be dominant markets for prothrombin complex concentrates, as most of the manufacturing facilities of prothrombin complex concentrates are located in these regions. However, the increasing demand for optimized & sustainable healthcare in countries of Asia Pacific, such as China and India, and of Middle-East is expected to fuel the growth of the prothrombin complex concentrates market.

The report finds the players operating in the market are laying emphasis on improving treatment options for patients with hemophilia B. Treatment with prothrombin complex concentrates is an economical option for warfarin reversal. It is has been observed that the treatment with prothrombin complex concentrates is the most economical option as it minimizes the hospital stay and laboratory costs. Direct healthcare costs including drug and hospital costs in Europe are approximately US$ 400,000 for prothrombin complex concentrates, whereas for warfarin withdrawal therapy, it was approximated US$ 1,200,000.

To remain ‘ahead’ of your competitors, request for a sample

Manufacturers tend to depend on plasma as a primary precursor to manufacture prothrombin complex concentrates, and in the past, they relied on third-party sources for plasma. Manufacturers are now opening their own plasma collection banks to reduce dependence on third-party sources. This trend has been observed to have grown since 2013. The key players operating in the market, such as CSL Behring & Shire, have scaled up their focus on depending on their own sources for plasma.

Compound pharmacies, retail pharmacies, and hospital pharmacies distributing prothrombin complex concentrates are the primary point of contact for patients experiencing hemophilia B and other disorders. The hospital pharmacies segment in the prothrombin complex concentrates market accounted for over 40% revenue share in 2017. The growing demand for cost-effective diagnostic options is also expected to propel the growth of the global prothrombin complex concentrates market over the forecast period.

The manufacturers of prothrombin complex concentrates are particularly focusing on acquisitions, collaborations, and opening plasma banks, where joint collaboration with various organizations is the prime activity to spread awareness regarding the efficiency of prothrombin complex concentrates.

The growing geriatric population & unmet hemophilia therapeutic needs are also expected to be important factors fueling the growth of the prothrombin complex concentrates market over the forecast period. The worldwide incidence of hemophilia is not well known and it is estimated that 75% of people with hemophilia receive inadequate treatment or have no access to the treatment. The growth in the global population over 65 years of age is expected to be the high impact driver for the growth of the market. As per the U.S. Census Board, around 13% of the U.S. population is above 65 years old and this figure is estimated to touch 20 % by the end of 2030.

Development of prothrombin complex concentrates and commercial production are highly intricate and complex. Prothrombin complex concentrates are prepared from pooled plasma. They pose a theoretical risk of transmitting infectious agents, which might survive the extraction and attenuation steps during the manufacturing process. There is a lack of substantial clinical evidence on contraindications and exclusion criteria, which is expected to hinder the growth of the prothrombin complex concentrates market over the forecast period.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-7032

Examples of some of the key participants operating in the prothrombin complex concentrates market analyzed in this report are

  • Shire
  • Octapharma AG
  • Nihon Pharmaceutical Co Ltd
  • Sanquin Blood Supply Foundation
  • CSL Behring GmbH
  • Kedrion Biopharma Inc
  • Grifols, S.A.

Additional Questions Answered

Readers can find detailed information about the important positive and negative factors affecting the prothrombin complex concentrates market during the forecast period. Additionally, the report also contains valuable information that can provide prothrombin complex concentrates manufacturers with answers to critical questions, such as

  • Which types of products account for the maximum demand for prothrombin complex concentrates market? Why is it so?
  • Why is the sale of prothrombin complex concentrates high in North America? What are the factors customers seek in prothrombin complex concentrates?
  • Which factors are influencing the strategies of players in the prothrombin complex concentrates market?
  • What are the current trends adopted by various companies?
  • What are the strategies being applied by the manufacturers in order to sustain themselves in the competitive market?

Segmentation

The report on the prothrombin complex concentrates market provides salient information on market players. The prothrombin complex concentrates market is segmented by region, product type, indication, and distribution channel, to analyze segment-wise growth of the prothrombin complex concentrates market.

Based on regions, the prothrombin complex concentrates market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding China & Japan (APECJ), Japan, China, and the Middle East & Africa (MEA). The prothrombin complex concentrates market by product type is segmented into 3-Factor prothrombin complex concentrates, and 4-factor prothrombin complex concentrates.

By indication, the prothrombin complex concentrates market is segregated into hemorrhagic episodes in factor IX defficiency – Haemiohilia B, trauma, life-threatening coagulopathy with acute bleeding, warfarin-associated acute, life threatening bleeding, and non-warfarin anticoagulant reversal with acute bleeding. By distribution channel, the prothrombin complex concentrates market is segregated into compound pharmacies, retail pharmacies, and hospital pharmacies.

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-7032

Continuous Peripheral Nerve Block Catheter Market to Reach US$ 742.7 Billion, Globally, by 2027 at 6.1% CAGR: FMI

Future Market Insights has delivered key insights and presented a revised forecast analysis on continuous peripheral nerve block catheters market in its new research study titled “Continuous Peripheral Nerve Block Catheter Market: Global Industry Analysis (2012-2016) and Forecast (2017-2027)”. Continuous peripheral nerve block catheter are increasingly being used for pain management in patients undergoing upper/lower extremity surgeries and patients suffering from trauma, owing to their advantages, such as meticulous precision and low-price. Continuous peripheral nerve block catheter are emerging as a credible alternative to opioids for pain management as ill-effects associated with opioids are very severe such as addiction to opioids

Global Continuous Peripheral Nerve Block Catheter Market: Forecast Highlights

The global continuous peripheral nerve block catheter market is anticipated to record a CAGR of 6.1% and the market is estimated to reach a value of US$ 742.7 Mn in 2027 from a valuation of around US$ 411 Mn in 2017.

To remain ‘ahead’ of your competitors, request for a sample

Global Continuous Peripheral Nerve Block Catheter Market: Segmental Analysis

The market is segmented based on product type, insertion technique, indication, end users and regions. On the basis of product type, the market has been segmented into stimulating catheter system, non-stimulating catheter systems and over-the-needle catheter systems. Non-stimulating catheter systems segment dominated the global continuous peripheral nerve block catheter market in terms of value and volume in 2017. This segment is expected to continue its dominating streak throughout the forecast period.

On the basis of insertion technique, the continuous peripheral nerve block catheter market has been segmented into nerve stimulation and ultrasound based insertion technique. Continuous peripheral nerve block catheter that uses ultrasound based insertion technique is expected to witness higher demand than devices that use nerve stimulation technique for catheter insertion. The ultrasound based insertion technique segment is projected to grow at a higher rate during the forecast period. However, the nerve stimulation based insertion technique segment is expected to show a higher market valuation.

On the basis of indication, the continuous peripheral nerve block catheter market has been segmented into trauma cases, upper extremity surgeries, lower extremity surgeries, pain management and other indications. Amongst these aforementioned segments, lower extremity surgeries segment is expected to witness higher revenue growth as compared to other segments over the forecast period and this segment is expected to show higher value CAGR throughout the period of assessment.

Key end-use sectors that generate the bulk of demand for continuous peripheral nerve block catheter can be broadly categorised into hospitals and ambulatory surgical centres. Among these, hospitals account for the largest revenue share of the market, owing to increasing number of hospitalisations for upper/lower extremity procedures carried out in hospitals. The hospital segment is a highly lucrative segment from an investment standpoint.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1307

FMI’s report has segmented the global continuous peripheral nerve block catheter market on the basis of region into North America, Western Europe, Eastern Europe, Latin America, Asia Pacific Excluding Japan (APEJ), Middle East & Africa and Japan. This report assesses trends driving each market segment and offers analysis and insights about the potential of continuous peripheral nerve block catheter in specific regions. The North America region is the leading region in terms of global revenue share, followed by Western Europe and Japan. North America is estimated to dominate the continuous peripheral nerve block catheter market with maximum value share of the overall market by end of 2017. North America continuous peripheral nerve block catheter market increase at a CAGR of 6.5% through 2027. Presence of key regional players, strong distribution network, and developed healthcare infrastructure are the key factors driving the growth of the market in North America.

Global Continuous Peripheral Nerve Block Catheter Market: Competitive Assessment

Some key players in the global continuous peripheral nerve block catheter market identified include:

B. Braun Melsungen AG,

Teleflex Incorporated,

Halyard Health, Inc.,

Epimed International Inc.

Pajunk GmbH.

Market Segmentation

By Product Type

Stimulating Catheter

Open Tip Catheter Stimulating Catheter

Closed Tip Catheter Stimulating Catheter

Non-Stimulating Catheter

Open Tip Catheter Non-Stimulating Catheter

Closed Tip Catheter Non-Stimulating Catheter

Over-The-Needle Catheter

By Insertion Technique

Nerve Stimulation Based Insertion

Ultrasound Based Insertion

By Indication

Trauma Cases

Upper Extremity Surgeries

Lower extremity Surgeries

Pain Management

Other Indications

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1307

By End User

Hospitals

Ambulatory Surgical Centers

By Region

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

Middle East & Africa

Systemic Infection Treatment Market Research Report: Key Drivers and Restraints, Opportunities, Industry Share & Trend Analysis Report to 2027

Systemic Infection are the type of pathogenic infection that spreads throughout the body. It can be comprised of bacterial, viral or fungal infections. The main characteristic of systemic infection is affecting the bloodstream of a person and thus spread to the whole body. The systemic infections can vary from the common ones such as cold, flu, strep throat or can be life-threatening like STDs. Conventional methods used for the diagnosis of these type of infections might delay the therapy process. Nowadays, modern day techniques such as ELISA and PCR are most used for more specific and quick results.  Treatment depends upon the type and severity of infection. Generally, antibacterial, antiviral and antifungal drugs are given for the treatment by either oral or intravenous mode of administration. Oral route of administration is the safest, economical and the easiest way of treatment. Nowadays, multi drug resistance is one of the growing concern for the treatment of pathogens. The treatment becomes difficult in some cases as infection spreads throughout the body.

By the increased number of people with reduced immune response has led to increased prevalence of systemic infections. On the other hand, a large number of anti-infectives are available in the market which thus increase the overall market of systemic infection treatment.

Systemic Infection Treatment Market: Drivers & Restraints

Systemic Infection Treatment market is likely to proliferate in the future as per existing trends for the increase in the patient pool across the globe. Large number of research studies these days has increased the number of treatment options with more efficient results which thus drives the growth of systemic infection treatment market. Funding and assistance programs by the government as well as non-government agencies are also aiding in the overall market increase. Microbial resistance to various anti-infectives is one of the limiting factor that curbs the market growth. Non-availability of drugs for deadly systemic infections such as HIV or the huge cost of treatment is also a hurdle for the market growth. Increase in number of key players in the market increases the competition which restricts new players to enter the market.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3423

Systemic Infection Treatment Market: Overview

With the ever increasing number of pharmaceutical industries and large number of products in the market intensifies the competition. Innovative and cost effective products would be the cutting edge to become a key player in the market. Generic competition is more in the market comprising 60% of the total sales. Novel biologics with improved drug delivery and target specific approach are the demand for the growing systemic infection treatment market. By maintaining the safety and efficacy of the drug will always pushes the companies towards growth. Many global key players have a large number of drugs for the systemic infection treatment in the pipeline which thus help in driving the market.

Systemic Infection Treatment Market: Region-wise Outlook

North America and European regions have the established market with large number of global key players in their market. This is due to the favorable health facilities and healthy reimbursement scenario in these developed nations. Furthermore, growth availability is seen in the countries of Asia-Pacific, Middle East and Africa, which has a large pool of patients with systemic infections. A huge number of pharmaceutical industry base is seen in growing economies like India and China with higher growth rate, thus increasing the opportunity for investment in these countries. Increasing awareness, health facilities and government efforts are the driving factors for the systemic infection treatment market growth in these countries.

Systemic Infection Treatment Market: Key Players

Some of the global key players manufacturing branded as well as generic therapeutic in Systemic Infection Treatment market include

  • Abbott Laboratories,
  • Merck & Co., Inc.,
  • Pfizer, Inc.,
  • GlaxoSmithKline plc,
  • Novartis AG,
  • Johnson & Johnson,
  • Sun Pharmaceuticals,
  • Roche,
  • Astra Zeneca plc,
  • Wockhardt ltd,
  • Mylan Pharmaceuticals Inc

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3423

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Systemic Infection Treatment Market: Segmentation

Segmentation by Treatment Type

  • Antibacterial
  • Antiviral
  • Antifungal

Segmentation by Mode of Administration

  • Oral
  • Intravenous
  • Topical

Segmentation by Drug Availability

  • Generic
  • Branded

Segmentation by Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3423

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

PARP Inhibitors Market Is Estimated To Be Valued At US$ 8.4 Billion By 2021 And Forecast To 2026

Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year. The incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.

The global PARP inhibitors market is estimated to be valued at US$ 8.4 Bn by 2026, expanding at a significant CAGR from 2019 to 2026.

“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period.”

Key Takeaways of PARP Inhibitors Market Study

Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2018, and will continue to do so during the forecast period.

PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.

“To remain ‘ahead’ of your competitors, request for a sample” – https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.

 

Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence

All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings. For example, in January 2019, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).

More Valuable Insights on PARP Inhibitors Market

Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2015 to 2026. The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on PARP inhibitors market on basis of drug (Olaparib, Niraparib, Rucaparib, and Talazoparib), indication (ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer), and distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), across seven major regions.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3197

PARP INHIBITORS MARKET TAXONOMY

The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib

Indication

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3197

Region

North America

Europe

Latin America

South Asia

East Asia

Oceania

Middle East And Africa

Clinical Trials Market Trends, Key Driven Factors, Region-wise Outlook, Segmentation And Forecast To 2021-2029

A new study of Future Market Insights (FMI) estimates the global spending on clinical trials in 2019 at ~US$ 90 Bn, recording a ~4% Y-o-Y over 2018. The healthcare sector is closing in on a new era of clinical trials, which are more engaged with patients, streamlined and connected. With development costs reaching record highs and patents approaching cliffs, companies are strengthening their R&D efforts to keep pace with change. Medical device and pharma giants are already eyeing better approaches for clinical trials, implementing a combination of their current systems and better technologies to ebb challenges in critical areas – orphan drugs and rare diseases.

“The ubiquity digital technologies is evidently growing, as these (including but not limited to ingestible devices, sensors, and wearable health monitors) hold the potential to disrupt the aspects of clinical trials. Digital technologies are revolutionizing the antiquated process of new drug development, even as optimizing the way health data is collected, measured, and assessed”.

According to the study, the clinical trials landscape is witnessing a paradigm shift toward patient centricity, in a bid to incorporate perspective of patients during the clinical trial design. Clinical trial sponsors have aligned their methods with the voice of patients, by launching communication channels during the study’s execution. Key enterprises are adopting unconventional approaches by implementing site-centric method, using operational support systems and technology for bringing studies to the trial-naïve physicians.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-384

Industry Sponsors Account for Majority Clinical Trial Spending

The most remarkable advances in medicine are realized from sponsorships of companies for clinical trials, in the anticipation of turning a profit. A notable percentage of clinical trials being conducted to support approval of vaccines, devices, or drugs, and track their safety, have been industry-sponsored in recent years.

The study estimates industry-sponsored clinical trials to account for ~60% of overall spending in 2019, and in the foreseeable future. Recent studies state that industry-sponsored trials yield positive results compared to academic-run trials, which also account for a significant share of clinical trial spending.

According to FMI, sponsors, such as academic institutes, research institutes and medical centers, are estimated to account for ~30% clinical trial spending in 2019. As the imperativeness of evidence-based therapies continue to be progressively emphasized, most of the randomized clinical trials are driven by the ability of developing profitable new therapies. Guidelines recommended by regulatory bodies for clinical trial enrichment, and risk-based monitoring are likely to lay the groundwork for more targeted approach toward cost-intensive clinical trials.

The study opines that North America and Europe will continue to lead the clinical trials landscape, collectively accounting for ~80% of global spending. These regions present a standardized and favorable environment for the clinical trials landscape, in light of their economic vigor that enables them to benefit from most of the technology disruptions prior to other nations. Pharmaceutical and medical device giants in these two regions are adopting AI for disrupting every stage of the clinical trial, which range from linking studies to eligible patients, to data collection and adherence.

According to the study, opportunities abound for conducting clinical trials in developing economies, such as in East Asia and South Asia, owing to the access to huge patient pool. Sponsors are likely to realize greater success in these regions as low government healthcare budgets represent cost-effective methods of providing patients with access to innovative therapies. Additionally, conducting clinical trials in these regions comes with other broader advantages, including pragmatic & efficient regulatory pathway, and tax incentives for conducting the trials.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-384

Key Segment

By Area

  • Oncology
  • Infectious Disease
  • Metabolic Disorders
  • Cardiovascular
  • Neuroscience
  • Respiratory
  • Others

By Phase

  • Phase 0
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Sponsor

  • Industry-sponsored
  • Government / Public
  • Non-governmental Organizations
  • Others (Academic Medical Centers, Individuals, etc.)

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-384

Molecular Diagnostics Market 2021 End-User Demand by Types, Regions,Top Players, Service Provides, Regional Outlook and Forecast to 2026

Molecular diagnostics is a method of analyzing and identifying the biological markers in the genome and proteome in order to identify gene expression by applying molecular biology. Molecular diagnostics are used to diagnose disease and risk involved. Molecular Diagnostics helps to decide the therapies are suitable for individual patients. The new advanced technologies has qualified the instruments in providing accurate results. This ability of the diagnostic tool resulted in increased rate of acceptance of the molecular diagnostics. The concept of personalized medicine has emerged out of molecular diagnostics.

Molecular Diagnostics Market: Drivers & Restraints

The factors driving molecular diagnostic market are increase in demand for care facilities, favorable regulatory policies which aims at promoting the care diagnosis, acceptance of personalized medicine, development in biomarkers, advancements in proteomics, increasing awareness of the diagnostic procedures. However rising cost of molecular diagnostics, obligation of skilled labors to handle the complexity of instruments are the factors restraining the growth of molecular diagnostics market.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1262

Molecular Diagnostics Market: Overview

The awareness of diagnosis is giving rise to the trend of self-care management. The early diagnosis of disease or disorder helps the patient in getting better treatment and cure. Infectious disease and Oncology is estimated to be the fastest growing application owing to the increased prevalence of cancer and demand for early diagnosis. The introduction to specific biomarkers for the treatment has a positive impact over the molecular diagnosis market. However maximum use of reagents is estimated owing to their accurate results. Commonly used reagents are salts, formamide, sodium dodecyl sulfate and dextran sulphate heparin. Growing awareness about the prenatal genetic testing for early detection of chromosomal abnormalities during pregnancy has enhanced the use of molecular diagnostics.

Molecular Diagnostics Market: Region-wise Outlook

Depending on geographic regions, the Global Molecular Diagnostics market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan, and Middle East & Africa. North America is estimated to be the largest player in molecular diagnostic market owing to the technological advancements and innovations, increase in R&D investments by large pharmaceutical and biotechnological industries and demand for early diagnosis. Asia Pacific is estimated in rising molecular diagnostic market due to increase in the prevalence of diseases such as cardiovascular diseases, infectious diseases and large population suffering from diabetes.

Molecular diagnostics Market: Key Players

Some of the key players identified in the molecular diagnostic market are Abbott laboratories, Becton Dickinson, Novartis, Roche Diagnostics, Johnson and Johnson, Bio-Rad Laboratories, bioMerieux, Danaher Corporation, Qiagen N.V, Siemens Healthcare, Cepheid, Hologic, Inc,.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1262

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil, Rest Of Latin America)
  • Western Europe (Germany, Italy, U.K, Spain, France, Rest of Western Europe)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Molecular Diagnostics Market: Segmentation

Molecular diagnostic market is classified on the basis of product, technology, application, end use and geography.

Based on product, the global molecular diagnostic market is segmented into the following:

  • Instruments
  • Reagents
  • Others (service and software)

Based on technology, the global molecular diagnostic market is segmented into the following:

  • DNA sequencing
  • Polymerase chain reaction
  • Isothermal Nucleic Acid Amplification Technology
  • Transcription Mediated Amplification (TMA)
  • In situ hybridization
  • Sequencing
  • Microarrays
  • Mass spectrometry
  • DNA sequencing
  • Others (southern blotting, northern blotting, electrophoresis)

Based on application, the global molecular diagnostic market is segmented into following:

  • Cancer
  • Pharmacogenomics
  • Genetic testing
  • Infectious disease
  • Prenatal
  • Neurological disease
  • Cardiovascular disease

Based on end use, the global molecular diagnostic market is segmented into following:

  • Diagnostic laboratories
  • Hospitals
  • Others( nursing home, blood banks, point of care)

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1262

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint